Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO 2019 Expert Video Report on Small Cell Lung Cancer

Reporting from ESMO 2019 Congress, Martin Reck comments on the results from 2 trials studying a combination of chemotherapy and immune checkpoint inhibitor in the first-line treatment of patients with extensive stage small cell lung cancer (SCLC), and a trial studying anlotinib in heavily pretreated patients with relapsed SCLC. He explains that after decades of research there are moderately positive results and more analysis is needed to identify meaningful biomarkers.

Abstracts:

  • 1736O: IMpower133: updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
  • 1738O: Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC)
  • LBA89: PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings